Prevalence of Documented Excessive Weight Gain Among Adolescent Girls and Young Women Using Depot Medroxyprogesterone Acetate

J Clin Med Res. 2019 May;11(5):326-331. doi: 10.14740/jocmr3792. Epub 2019 Apr 14.


Background: Depot medroxyprogesterone acetate (DMPA) is an accessible contraception with high efficacy among adolescents. However, concern of weight gain can impede DMPA use. The objective of this study was to determine prevalence of excessive weight gain associated with DMPA injection in young women and its predicting factor.

Methods: This retrospective chart review included young women aged 10 - 24 years who had used DMPA and attended at Family Planning and Reproductive Medicine Unit, Siriraj Hospital for at least 6-month period during January 2010 to June 2016. Baseline clinical data, weight at beginning of contraception, and weight at 6 and 12 months thereafter were reviewed. Excessive weight was defined as weight gain of > 5% of their baseline weight at 6 months. Various baseline variables were compared between groups with and without excessive weight gain.

Results: Among 231 DMPA users in this study, there were 28 women (12.1%, 95% confidence interval (CI): 7.8 - 16.3) who had an excessive weight gain at 6 months. Age, baseline body mass index, or race did not affect the likelihood of excessive weight gain. The excessive weight gain group had significant higher proportion of nulliparity, unmarried status and DMPA-ever used history compared to another one. Six of 13 (46.2%) excessive weight gainers at 6 months who continued DMPA use had gain even more weight (> 10% of their baseline weigh) at 12 months.

Conclusions: The majority of adolescent girls using DMPA had no excessive weight gain in 6 months. However, DMPA users who had excessive weight at 6 months were at high risk of gaining even more weight at 1 year.

Keywords: Adolescent; Contraception; DMPA; Weight gain; Young women.